Neural mediation of the motilin motor effect on the human antrum.
To elucidate the mode of action of motilin on the stimulation of human gastrointestinal motility, we studied the effect of exogenous motilin during muscarinic or serotoninergic pharmacological blockade. Manometric recording of the interdigestive antroduodenal motility was carried out in 27 healthy volunteers until the appearance of a spontaneous antral phase III. The tested blocker was then administered intravenously and was followed 30 min later by a 10-min infusion of synthetic human motilin (50 ng/kg). Motilin administered on a background of saline induced a premature phase III migrating from the antrum to the duodenum in every tested subject (n = 5). A low dose of atropine (5 micrograms.kg-1.h-1 for 90 min) inhibited the motilin effect in two of five subjects [not significant (NS)], whereas a high dose of atropine (15 micrograms/kg given in 30 min) blocked the motilin-induced premature antral phase III in all instances (n = 5, P < 0.01). Exogenous motilin given with low-dose ondanseton (8 mg given in 15 min followed by 1 mg/h for 90 min) or high-dose ondansetron (32 mg given in 30 min) was without effect in three of seven (NS) or in two of five (NS) subjects, respectively. During the administration of 15 micrograms/kg atropine, when exogenous motilin always failed to induce a premature antral phase III motor, a phase III-type activity was generated at the duodenum in four of five subjects. We conclude that the induction by motilin of phase III activity in human antrum is dependent on muscarinic mediation and that the contractile effect of motilin on human duodenum involves a noncholinergic mechanism, different therefore from the antral pathway.
Boivin
M
M
Hôpital Saint-Luc, Université de Montréal, Québec, Canada.
Pinelo
L R
LR
St-Pierre
S
S
Poitras
P
P
D000293:Adolescent; D000328:Adult; D001285:Atropine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004386:Duodenum / Q000187:drug effects; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D008297:Male; D008365:Manometry; D008875:Middle Aged; D009037:Motilin / Q000494:pharmacology*; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009424:Nervous System Physiological Phenomena; D017294:Ondansetron / Q000494:pharmacology; D011706:Pyloric Antrum / Q000187:drug effects*; D012702:Serotonin Antagonists / Q000494:pharmacology
D018727:Muscarinic Antagonists; D012702:Serotonin Antagonists; D017294:Ondansetron; D009037:Motilin; D001285:Atropine